APOE Genotype (E2/E3/E4) Test

Your APOE genotype (apolipoprotein E genotype) is one of the most powerful single pieces of genetic information available in preventive medicine. It tells you which version of a fat-carrying protein your body produces, and that version shapes your risk for Alzheimer's disease, heart disease, stroke, and even how long you are likely to live. Unlike most blood tests, this one never changes. You are born with your result, and it applies for life.

The reason this test matters so much is that the three common versions of the APOE protein (called E2, E3, and E4) differ by just two tiny building blocks in their structure, yet those differences dramatically change how your body handles cholesterol, clears debris from your brain, and responds to inflammation. Knowing which combination you carry gives you a personal risk profile that standard cholesterol tests and cognitive screenings cannot provide.

The Three Versions and What They Mean

Everyone inherits two copies of the APOE gene, one from each parent, creating six possible genotype combinations: E2/E2, E2/E3, E2/E4, E3/E3, E3/E4, and E4/E4. The E3 version is the most common, carried by 50% to 90% of people depending on ancestry, and serves as the baseline reference. E4 is the version associated with higher disease risk, while E2 is generally protective.

About 75% of the APOE protein circulating in your blood is made by your liver, where it acts as a shuttle for cholesterol and triglycerides. But APOE is also produced in your brain, primarily by support cells called astrocytes, where it distributes cholesterol and fats to neurons. The brain and blood pools of APOE operate independently and do not cross the blood-brain barrier, which is why the same gene variant can affect both your heart and your brain through different mechanisms.

Alzheimer's Disease Risk

APOE is the strongest common genetic risk factor for late-onset Alzheimer's disease. In a study of over 12,000 people from the Rotterdam Study, the cumulative risk of developing Alzheimer's by age 85 was 48% for E4/E4 carriers, 18% for E3/E4 carriers, 9% for E3/E3 carriers, and just 6% for those with at least one E2 copy. That means people who carry two copies of E4 (called E4 homozygotes) face roughly five times the risk of the average person, while carrying even one E2 copy cuts the risk by about 40%.

When APOE genotype was combined with a broader genetic risk score in the same study, the spread became even more striking. E4/E4 carriers in the highest genetic risk group reached a 63% chance of Alzheimer's by age 85, while E2 carriers in the lowest risk group had just a 4% chance. That is a 59 percentage point gap driven largely by genetics you can test for today.

One detail that often gets lost: APOE E4 primarily shifts when you develop Alzheimer's, not whether you will. Carriers tend to develop symptoms 10 to 20 years earlier than non-carriers. And more than half of E4/E4 homozygotes still do not develop Alzheimer's by age 85. Carrying E4 is a risk factor, not a diagnosis.

Ancestry Changes the Math

The strength of the E4/Alzheimer's link varies significantly by population. In a large multi-ancestry analysis, the risk multiplier for E3/E4 carriers compared to E3/E3 was 4.54 in East Asian populations, 3.46 in non-Hispanic White populations, 2.18 in non-Hispanic Black populations, and 1.90 in Hispanic populations. The protective effect of E2 also differs: it significantly reduces risk in White populations but shows no measurable protection in East Asian populations. Risk estimates derived from predominantly White study populations should not be applied directly to people of other backgrounds.

Sex matters too. Among non-Hispanic White individuals, E3/E4 women between ages 60 and 70 face about 50% greater Alzheimer's risk than E3/E4 men in the same age range. This sex difference has been replicated in Black and Hispanic populations as well.

Heart Disease and Stroke

APOE E4 raises LDL cholesterol by an average of about 6 mg/dL compared to E3/E3, while E2 lowers it by about 17 mg/dL. These shifts have real cardiovascular consequences. A meta-analysis of 48 studies found that E4 carriers had a 42% higher risk of coronary heart disease. Another meta-analysis of 30 studies, including nearly 12,000 heart disease cases, showed that E4/E4 homozygotes had a 45% increased risk compared to E3/E3.

For stroke, a meta-analysis of 55 studies covering over 12,000 cases found E4 carriers were about 37% more likely to have an ischemic stroke (the kind caused by a blood clot). E4/E4 homozygotes faced an 83% higher risk. On the protective side, E2/E3 carriers had a 15% lower risk of ischemic stroke.

The E2 Paradox

E2 is generally the protective version: lower LDL, lower Alzheimer's risk, longer lifespan. But E2/E2 homozygotes (about 2% to 3% of the population) face a specific and somewhat counterintuitive risk. Because the E2 protein does not bind as well to the receptors that clear leftover fat particles from the blood, E2/E2 carriers can develop a condition called type III hyperlipoproteinemia (a buildup of leftover fat particles in the blood), where these remnant particles accumulate and drive aggressive atherosclerosis (plaque buildup in the arteries).

Data from the Copenhagen population cohorts also found that E2/E2 homozygotes had a 49% higher risk of peripheral arterial disease (reduced blood flow to the legs) compared to E3/E3 carriers. A large UK Biobank analysis confirmed that E2/E2 homozygosity (carrying two copies of E2) also increases the risk of blood clots and arterial aneurysm. These risks do not cancel out E2's survival advantage on the whole, but they mean E2/E2 carriers should pay extra attention to their lipid profile.

Longevity and All-Cause Mortality

The E2-CHARGE consortium pooled data from over 38,000 people across six population-based studies, tracking more than 17,000 deaths over an average of nearly 12 years. E4 carriers had a 17% higher risk of dying from any cause compared to E3/E3 carriers, with E4/E4 homozygotes facing a 52% higher risk. E2 carriers, by contrast, had about a 6% lower risk of death.

Source: E2-CHARGE consortium, Wolters et al. (38,537 participants, six cohorts, mean 11.7-year follow-up).

When researchers censored for dementia (meaning they removed the effect of dementia-related deaths), the E4-mortality link weakened considerably, dropping from a 17% to a 7% increase. This suggests that much of the excess mortality associated with E4 is driven by its effect on Alzheimer's disease and dementia. The Copenhagen General Population Study, with over 105,000 participants, confirmed these patterns and added that E4/E4 carriers also had a 28% higher risk of cardiovascular death and an 18% higher risk of cancer death.

Cancer Associations

A 2025 meta-analysis of 38 studies found that cancer risk increased modestly from E2 to E3 to E4 across all cancer types combined. The clearest signal was for lung cancer, where E2/E2 carriers had a 52% higher risk and E4 carriers had a nearly threefold higher risk compared to E3/E3. Colorectal cancer showed a smaller effect, with E4/E3 carriers having about a 7% increased risk. One interesting exception: for melanoma (skin cancer), the pattern reversed entirely. E4 was associated with better outcomes and E2 with worse ones.

Genotype Categories

Because APOE genotype is a fixed genetic result (not a number that fluctuates), there are no traditional reference ranges. Instead, results are interpreted by genotype category and the disease-risk profile each one carries.

These frequencies are approximate and vary by ancestry. The risk profiles summarize average effects across large populations. Your individual risk is shaped by your full genetic background, lifestyle, and other health conditions.

Why Your Result Is Permanent

Unlike most biomarkers covered on this site, your APOE genotype is determined at conception and never changes. Your DNA sequence is the same in every cell of your body, at every age, regardless of illness, medication, diet, or anything else. This means you only need to take this test once. A second test would give the same result.

This permanence is actually a strength. Instead of tracking a number that bounces around with meals, hydration, and sleep, you get a single, definitive data point that shapes how you interpret every other test you take. If you carry E4, you know your LDL cholesterol has a higher baseline, your brain's ability to clear amyloid (a sticky protein that builds up in Alzheimer's disease) may be slower, and certain medications carry different risk-benefit calculations. That context applies for the rest of your life.

How APOE Shapes Your Response to Treatment

Knowing your APOE genotype is becoming directly relevant to treatment decisions. For Alzheimer's disease, a new class of drugs called anti-amyloid antibodies (such as lecanemab) requires APOE genotyping before treatment because E4 carriers, especially E4/E4 homozygotes, face a substantially higher risk of a side effect called ARIA, which involves brain swelling or small bleeds visible on MRI. In some countries, E4/E4 homozygotes are excluded from treatment entirely.

For cardiovascular treatment, E2 carriers may respond more strongly to statin therapy in terms of LDL reduction compared to E4 carriers, though the clinical significance of this gene-drug interaction is still debated. Regardless, your genotype can inform how aggressively you and your physician approach lipid management.

What This Test Cannot Tell You

APOE genotyping identifies genetic susceptibility. It does not diagnose any disease, and it does not tell you whether disease has already started. An E4/E4 carrier with no symptoms may never develop Alzheimer's, and an E3/E3 carrier is not immune. The test has a sensitivity of roughly 50% to 70% for Alzheimer's (meaning it misses 30% to 50% of cases) and a specificity of about 85% to 91%.

If you want to know whether amyloid plaques are currently forming in your brain, you would need a different kind of test entirely: either a spinal fluid analysis measuring amyloid and tau proteins, a blood-based biomarker panel (such as plasma p-tau217), or an amyloid PET brain scan. APOE genotyping tells you about your genetic starting position. These other tests tell you where you are right now.